SLC11A2 and cancer: Turcu et al. found that divalent metal transporter 1 (DMT1) inhibitors selectively target cancer stem cells by blocking lysosomal iron transport, resulting in the accumulation of lysosomal iron, the production of reactive oxygen species (ROS) and ferroptosis.